<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Histone Deacetylase Superfamily Review - CellNucleus.com</title>
    <link href="https://cdn.jsdelivr.net/npm/tailwindcss@2.2.19/dist/tailwind.min.css" rel="stylesheet">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.4.0/css/all.min.css">
    <style>
        .category-badge {
            background: linear-gradient(135deg, #8E44AD, #9B59B6);
        }
        .hero-image {
            background: linear-gradient(rgba(142, 68, 173, 0.1), rgba(142, 68, 173, 0.1));
        }
        .table-of-contents a {
            transition: all 0.3s ease;
        }
        .table-of-contents a:hover {
            color: #8E44AD;
            transform: translateX(5px);
        }
        .sidebar-section {
            background: linear-gradient(135deg, #f8f9fa, #e9ecef);
            border-left: 4px solid #8E44AD;
        }
        .main-content h3 {
            color: #2d3748;
            border-bottom: 2px solid #8E44AD;
            padding-bottom: 0.5rem;
        }
        .main-content h4 {
            color: #4a5568;
        }
        .key-points li::before {
            content: "▶";
            color: #8E44AD;
            font-weight: bold;
            margin-right: 0.5rem;
        }
    </style>
</head>
<body class="bg-gray-50 font-sans">
    <!-- Header -->
    <header class="bg-white shadow-md sticky top-0 z-50">
        <div class="container mx-auto px-4 py-3">
            <nav class="flex items-center text-sm text-gray-600 mb-2">
                <a href="#" class="hover:text-purple-600">Home</a>
                <i class="fas fa-chevron-right mx-2 text-xs"></i>
                <a href="#" class="hover:text-purple-600">Epigenetics & Gene Regulation</a>
                <i class="fas fa-chevron-right mx-2 text-xs"></i>
                <span class="text-gray-800">Histone Deacetylase Superfamily Review</span>
            </nav>
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <span class="category-badge text-white px-3 py-1 rounded-full text-sm font-medium">
                        Epigenetics & Gene Regulation
                    </span>
                    <h1 class="text-2xl font-bold text-gray-800">CellNucleus.com</h1>
                </div>
                <div class="hidden md:flex items-center space-x-6 text-sm">
                    <span><i class="fas fa-calendar-alt text-purple-600"></i> Published: June 2024</span>
                    <span><i class="fas fa-clock text-purple-600"></i> 45 min read</span>
                </div>
            </div>
        </div>
    </header>

    <div class="container mx-auto px-4 py-8">
        <div class="grid grid-cols-1 lg:grid-cols-4 gap-8">
            <!-- Main Content -->
            <main class="lg:col-span-3">
                <!-- Title Section -->
                <div class="bg-white rounded-lg shadow-lg p-8 mb-8">
                    <h1 class="text-4xl font-bold text-gray-800 mb-4">
                        Histone Deacetylase Superfamily: From Catalytic Mechanisms to Therapeutic Frontiers
                    </h1>
                    <div class="flex flex-wrap items-center text-sm text-gray-600 mb-6">
                        <span class="mr-6"><i class="fas fa-user text-purple-600"></i> Dr. Michael Hendzel, University of Alberta</span>
                        <span class="mr-6"><i class="fas fa-calendar text-purple-600"></i> Last Updated: June 27, 2025</span>
                        <span><i class="fas fa-clock text-purple-600"></i> Reading Time: 45 minutes</span>
                    </div>
                    
                    <!-- Hero Image -->
                    <div class="hero-image rounded-lg p-6 mb-6">
                        <div class="bg-gray-200 h-64 rounded-lg flex items-center justify-center mb-4">
                            <div class="text-center text-gray-600">
                                <i class="fas fa-microscope text-6xl mb-4 text-purple-600"></i>
                                <p class="text-lg font-medium">Super-resolution Chromatin Microscopy</p>
                                <p class="text-sm">Chromatin decondensation and histone modification dynamics</p>
                            </div>
                        </div>
                        <p class="text-sm text-gray-600 italic text-center">
                            Super-resolution microscopy revealing chromatin decondensation and the dynamic regulation of histone modifications. 
                            Image courtesy of Nature Scientific Reports, doi:10.1038/srep04477
                        </p>
                    </div>

                    <!-- Abstract -->
                    <div class="bg-purple-50 border-l-4 border-purple-600 p-6 mb-8">
                        <h2 class="text-xl font-bold text-gray-800 mb-4">Abstract</h2>
                        <p class="text-gray-700 leading-relaxed">
                            The human histone deacetylase (HDAC) superfamily comprises 18 enzymes that serve as master regulators of the cellular acetylome, 
                            controlling gene expression, chromatin structure, and cellular homeostasis. This comprehensive review examines the classification, 
                            catalytic mechanisms, biological functions, and therapeutic targeting of both zinc-dependent and NAD+-dependent deacetylases.
                        </p>
                    </div>

                    <!-- Key Points -->
                    <div class="mb-8">
                        <h2 class="text-xl font-bold text-gray-800 mb-4">Key Points</h2>
                        <ul class="key-points space-y-3 text-gray-700">
                            <li>The HDAC superfamily consists of 18 enzymes classified into four classes based on sequence homology and cofactor requirements</li>
                            <li>Class I, II, and IV HDACs are zinc-dependent metalloproteases, while Class III sirtuins require NAD+ as a cofactor</li>
                            <li>HDACs target thousands of acetylated lysine residues on nuclear, cytoplasmic, and mitochondrial proteins</li>
                            <li>Aberrant HDAC expression is implicated in cancer, neurodegeneration, metabolic disorders, and inflammatory diseases</li>
                            <li>HDAC inhibitors represent a promising therapeutic strategy with several FDA-approved drugs for cancer treatment</li>
                        </ul>
                    </div>

                    <!-- Table of Contents -->
                    <div class="bg-gray-50 rounded-lg p-6 mb-8">
                        <h2 class="text-xl font-bold text-gray-800 mb-4">Table of Contents</h2>
                        <ol class="table-of-contents space-y-2 text-gray-700">
                            <li><a href="#section1" class="hover:text-purple-600">1. Introduction to Lysine Acylation and Cellular Regulation</a></li>
                            <li><a href="#section2" class="hover:text-purple-600">2. Classification and Cofactor Dependencies of Human HDACs</a></li>
                            <li><a href="#section3" class="hover:text-purple-600">3. Part I: Zinc-Dependent Deacetylases (Classes I, II, and IV)</a></li>
                            <li><a href="#section4" class="hover:text-purple-600">4. Class I HDACs: Nuclear Transcriptional Regulators</a></li>
                            <li><a href="#section5" class="hover:text-purple-600">5. Class IIa HDACs: Signal-Responsive Shuttling Enzymes</a></li>
                            <li><a href="#section6" class="hover:text-purple-600">6. Class IIb HDACs: Cytoplasmic and Specialized Functions</a></li>
                            <li><a href="#section7" class="hover:text-purple-600">7. Part II: NAD+-Dependent Deacylases (Class III Sirtuins)</a></li>
                            <li><a href="#section8" class="hover:text-purple-600">8. Sirtuin Family: Cellular Energy Sensors and Longevity Regulators</a></li>
                            <li><a href="#section9" class="hover:text-purple-600">9. HDAC Redundancy, Specificity, and Functional Overlap</a></li>
                            <li><a href="#section10" class="hover:text-purple-600">10. Disease Implications and Therapeutic Targeting Strategies</a></li>
                        </ol>
                    </div>
                </div>

                <!-- Main Content Sections -->
                <div class="main-content bg-white rounded-lg shadow-lg p-8 space-y-8">
                    <section id="section1">
                        <h3 class="text-2xl font-bold mb-4">1. Introduction to Lysine Acylation and Cellular Regulation</h3>
                        <p class="text-gray-700 mb-4">
                            Post-translational modifications represent fundamental mechanisms by which cellular complexity emerges from the finite genome. 
                            Among these modifications, reversible lysine acylation has emerged as a central regulatory node influencing gene expression, 
                            metabolism, signal transduction, and protein stability.
                        </p>
                        
                        <h4 class="text-lg font-semibold mb-3">Historical Context</h4>
                        <p class="text-gray-700 mb-4">
                            The discovery of histone acetylation in the 1960s marked the beginning of our understanding of epigenetic regulation. 
                            The subsequent identification of histone acetyltransferases (HATs) and histone deacetylases (HDACs) revealed the dynamic 
                            nature of chromatin modification.
                        </p>

                        <h4 class="text-lg font-semibold mb-3">Functional Significance</h4>
                        <p class="text-gray-700 mb-2">Lysine acetylation serves multiple regulatory functions:</p>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4">
                            <li>Neutralization of positive lysine charges affecting protein-DNA interactions</li>
                            <li>Creation of binding sites for bromodomain-containing proteins</li>
                            <li>Regulation of protein stability and subcellular localization</li>
                            <li>Modulation of enzyme activity and protein-protein interactions</li>
                        </ul>
                    </section>

                    <section id="section2">
                        <h3 class="text-2xl font-bold mb-4">2. Classification and Cofactor Dependencies of Human HDACs</h3>
                        <p class="text-gray-700 mb-4">
                            The 18 human HDACs are categorized into four classes based on sequence homology to yeast orthologs, 
                            cofactor requirements, and catalytic mechanisms.
                        </p>

                        <h4 class="text-lg font-semibold mb-3">Class Distribution</h4>
                        <div class="bg-gray-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Class I:</strong> HDAC1, 2, 3, 8 (nuclear, zinc-dependent)</li>
                                <li><strong>Class IIa:</strong> HDAC4, 5, 7, 9 (shuttling, zinc-dependent)</li>
                                <li><strong>Class IIb:</strong> HDAC6, 10 (cytoplasmic, zinc-dependent)</li>
                                <li><strong>Class IV:</strong> HDAC11 (nuclear/cytoplasmic, zinc-dependent)</li>
                                <li><strong>Class III:</strong> SIRT1-7 (diverse localization, NAD+-dependent)</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">Cofactor Requirements</h4>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4">
                            <li><strong>Zinc-Dependent Classes (I, II, IV):</strong> Require Zn²⁺ for catalytic activity</li>
                            <li><strong>NAD+-Dependent Class (III):</strong> Utilize NAD+ as stoichiometric cofactor</li>
                        </ul>
                    </section>

                    <section id="section3">
                        <h3 class="text-2xl font-bold mb-4">3. Part I: Zinc-Dependent Deacetylases (Classes I, II, and IV)</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">Structural Architecture</h4>
                        <p class="text-gray-700 mb-2">All zinc-dependent HDACs share a conserved catalytic domain containing:</p>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4 mb-4">
                            <li>Active site zinc ion coordinated by two aspartate and one histidine residue</li>
                            <li>Catalytic tyrosine residue for substrate positioning</li>
                            <li>Substrate binding tunnel accommodating acetylated lysine</li>
                        </ul>

                        <h4 class="text-lg font-semibold mb-3">Catalytic Mechanism</h4>
                        <p class="text-gray-700 mb-2">The deacetylation reaction proceeds through:</p>
                        <ol class="list-decimal list-inside text-gray-700 space-y-1 ml-4">
                            <li>Substrate binding and zinc coordination</li>
                            <li>Nucleophilic attack by zinc-activated water molecule</li>
                            <li>Tetrahedral intermediate formation</li>
                            <li>Product release and enzyme regeneration</li>
                        </ol>
                    </section>

                    <section id="section4">
                        <h3 class="text-2xl font-bold mb-4">4. Class I HDACs: Nuclear Transcriptional Regulators</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">HDAC1 and HDAC2</h4>
                        <div class="bg-blue-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Complexes:</strong> NuRD, Sin3A, CoREST complexes</li>
                                <li><strong>Functions:</strong> Transcriptional repression, DNA repair, cell cycle control</li>
                                <li><strong>Substrates:</strong> Core histones, p53, Rb, E2F1</li>
                                <li><strong>Disease Relevance:</strong> Cancer, neurodegeneration</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">HDAC3</h4>
                        <div class="bg-green-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Complexes:</strong> NCoR/SMRT corepressor complexes</li>
                                <li><strong>Functions:</strong> Circadian regulation, metabolism, inflammatory responses</li>
                                <li><strong>Unique Features:</strong> Requires association with NCoR/SMRT for activity</li>
                                <li><strong>Therapeutic Targeting:</strong> Metabolic diseases, cancer</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">HDAC8</h4>
                        <div class="bg-yellow-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Characteristics:</strong> Monomeric enzyme, unique among Class I HDACs</li>
                                <li><strong>Functions:</strong> SMC3 deacetylation, cell cycle progression</li>
                                <li><strong>Disease Associations:</strong> Cornelia de Lange syndrome, cancer</li>
                                <li><strong>Structural Features:</strong> Flexible active site enabling substrate diversity</li>
                            </ul>
                        </div>
                    </section>

                    <section id="section5">
                        <h3 class="text-2xl font-bold mb-4">5. Class IIa HDACs: Signal-Responsive Shuttling Enzymes</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">HDAC4, 5, 7, 9</h4>
                        <div class="bg-purple-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Localization:</strong> Nuclear-cytoplasmic shuttling regulated by phosphorylation</li>
                                <li><strong>Functions:</strong> Muscle differentiation, bone development, neuronal function</li>
                                <li><strong>Regulation:</strong> 14-3-3 protein binding, CRM1-mediated export</li>
                                <li><strong>Substrates:</strong> Primarily non-histone proteins including transcription factors</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">Unique Features</h4>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4">
                            <li>Large N-terminal regulatory domains</li>
                            <li>Tissue-specific expression patterns</li>
                            <li>Signal-dependent subcellular localization</li>
                            <li>Association with MEF2 transcription factors</li>
                        </ul>
                    </section>

                    <section id="section6">
                        <h3 class="text-2xl font-bold mb-4">6. Class IIb HDACs: Cytoplasmic and Specialized Functions</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">HDAC6</h4>
                        <div class="bg-red-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Localization:</strong> Predominantly cytoplasmic</li>
                                <li><strong>Substrates:</strong> α-tubulin, cortactin, HSP90</li>
                                <li><strong>Functions:</strong> Microtubule dynamics, protein trafficking, stress responses</li>
                                <li><strong>Unique Features:</strong> Two catalytic domains, zinc-finger ubiquitin binding domain</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">HDAC10</h4>
                        <div class="bg-indigo-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Characteristics:</strong> Cytoplasmic localization, polyamine deacetylase activity</li>
                                <li><strong>Functions:</strong> Autophagy regulation, DNA repair</li>
                                <li><strong>Substrates:</strong> Polyamines, selected proteins</li>
                                <li><strong>Disease Relevance:</strong> Cancer, neurodegeneration</li>
                            </ul>
                        </div>
                    </section>

                    <section id="section7">
                        <h3 class="text-2xl font-bold mb-4">7. Part II: NAD+-Dependent Deacylases (Class III Sirtuins)</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">Evolutionary Origin</h4>
                        <p class="text-gray-700 mb-4">
                            Sirtuins are evolutionarily conserved from bacteria to humans, reflecting their fundamental importance in 
                            cellular metabolism and survival.
                        </p>

                        <h4 class="text-lg font-semibold mb-3">Catalytic Mechanism</h4>
                        <p class="text-gray-700 mb-2">Sirtuins utilize NAD+ as a stoichiometric cofactor, producing:</p>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4">
                            <li>Deacylated substrate</li>
                            <li>Nicotinamide</li>
                            <li>O-acetyl-ADP-ribose</li>
                        </ul>
                    </section>

                    <section id="section8">
                        <h3 class="text-2xl font-bold mb-4">8. Sirtuin Family: Cellular Energy Sensors and Longevity Regulators</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">Nuclear Sirtuins</h4>
                        <div class="bg-teal-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>SIRT1:</strong> Histone deacetylation, p53 regulation, metabolic control</li>
                                <li><strong>SIRT6:</strong> DNA repair, telomere maintenance, glucose homeostasis</li>
                                <li><strong>SIRT7:</strong> rRNA transcription, ribosome biogenesis</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">Cytoplasmic Sirtuins</h4>
                        <div class="bg-orange-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>SIRT2:</strong> Tubulin deacetylation, cell cycle regulation</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">Mitochondrial Sirtuins</h4>
                        <div class="bg-pink-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>SIRT3:</strong> Metabolic enzyme deacetylation, oxidative stress response</li>
                                <li><strong>SIRT4:</strong> ADP-ribosylation, metabolic regulation</li>
                                <li><strong>SIRT5:</strong> Desuccinylation, demalonylation, metabolic control</li>
                            </ul>
                        </div>
                    </section>

                    <section id="section9">
                        <h3 class="text-2xl font-bold mb-4">9. HDAC Redundancy, Specificity, and Functional Overlap</h3>
                        <p class="text-gray-700 mb-4">
                            The HDAC superfamily exhibits both functional redundancy and specific roles, particularly evident in 
                            HDAC1/HDAC2 relationships.
                        </p>

                        <h4 class="text-lg font-semibold mb-3">Compensatory Mechanisms</h4>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4 mb-4">
                            <li>Overlapping substrate specificity</li>
                            <li>Shared complex associations</li>
                            <li>Developmental compensation</li>
                        </ul>

                        <h4 class="text-lg font-semibold mb-3">Functional Specialization</h4>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4">
                            <li>Tissue-specific expression</li>
                            <li>Unique substrate preferences</li>
                            <li>Distinct regulatory mechanisms</li>
                        </ul>
                    </section>

                    <section id="section10">
                        <h3 class="text-2xl font-bold mb-4">10. Disease Implications and Therapeutic Targeting Strategies</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">Cancer Applications</h4>
                        <div class="bg-red-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Approved HDAC Inhibitors:</strong> Vorinostat, romidepsin, belinostat, panobinostat</li>
                                <li><strong>Mechanisms:</strong> Tumor suppressor reactivation, apoptosis induction</li>
                                <li><strong>Combination Therapies:</strong> DNA methyltransferase inhibitors, immunotherapy</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">Neurological Disorders</h4>
                        <div class="bg-blue-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Targets:</strong> Memory formation, neuroprotection, synaptic plasticity</li>
                                <li><strong>Therapeutic Potential:</strong> Alzheimer's disease, Huntington's disease</li>
                                <li><strong>Challenges:</strong> Blood-brain barrier penetration, selectivity</li>
                            </ul>
                        </div>

                        <h4 class="text-lg font-semibold mb-3">Metabolic Diseases</h4>
                        <div class="bg-green-50 p-4 rounded-lg mb-4">
                            <ul class="space-y-2 text-gray-700">
                                <li><strong>Sirtuin Activators:</strong> Resveratrol, synthetic SIRT1 activators</li>
                                <li><strong>Applications:</strong> Diabetes, obesity, aging-related disorders</li>
                                <li><strong>Mechanisms:</strong> Metabolic enzyme regulation, mitochondrial biogenesis</li>
                            </ul>
                        </div>
                    </section>

                    <!-- Clinical Applications -->
                    <section class="bg-gray-50 p-6 rounded-lg">
                        <h3 class="text-2xl font-bold mb-4">Clinical Applications</h3>
                        
                        <h4 class="text-lg font-semibold mb-3">Therapeutic Development</h4>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4 mb-4">
                            <li><strong>Pan-HDAC Inhibitors:</strong> Broad-spectrum activity, significant toxicity</li>
                            <li><strong>Selective Inhibitors:</strong> Class- or isoform-specific targeting</li>
                            <li><strong>Combination Strategies:</strong> Synergistic effects with other epigenetic drugs</li>
                            <li><strong>Biomarker Development:</strong> Predictive markers for treatment response</li>
                        </ul>

                        <h4 class="text-lg font-semibold mb-3">Drug Resistance Mechanisms</h4>
                        <ul class="list-disc list-inside text-gray-700 space-y-1 ml-4">
                            <li><strong>Upregulation:</strong> Compensatory HDAC expression</li>
                            <li><strong>Mutations:</strong> Active site modifications</li>
                            <li><strong>Efflux Pumps:</strong> Increased drug export</li>
                            <li><strong>Alternative Pathways:</strong> Bypass mechanisms</li>
                        </ul>
                    </section>
                </div>
            </main>

            <!-- Sidebar -->
            <aside class="lg:col-span-1 space-y-6">
                <!-- Related Reviews -->
                <div class="sidebar-section bg-white rounded-lg p-6">
                    <h3 class="text-lg font-bold text-gray-800 mb-4">
                        <i class="fas fa-link text-purple-600 mr-2"></i>Related Reviews
                    </h3>
                    <ul class="space-y-3">
                        <li><a href="#" class="text-blue-600 hover:text-purple-600 text-sm">Histone PTMs Comprehensive Review</a></li>
                        <li><a href="#" class="text-blue-600 hover:text-purple-600 text-sm">Epigenetic Inheritance Complete</a></li>
                        <li><a href="#" class="text-blue-600 hover:text-purple-600 text-sm">Chromatin Remodeling Complexes Review</a></li>
                        <li><a href="#" class="text-blue-600 hover:text-purple-600 text-sm">Eukaryotic Gene Expression Review</a></li>
                    </ul>
                </div>

                <!-- Key Terms -->
                <div class="sidebar-section bg-white rounded-lg p-6">
                    <h3 class="text-lg font-bold text-gray-800 mb-4">
                        <i class="fas fa-book text-purple-600 mr-2"></i>Key Terms
                    </h3>
                    <dl class="space-y-3 text-sm">
                        <dt class="font-semibold text-gray-800">Histone Deacetylases (HDACs)</dt>
                        <dd class="text-gray-600 ml-4">Enzymes that remove acetyl groups from lysine residues</dd>
                        
                        <dt class="font-semibold text-gray-800">Sirtuins</dt>
                        <dd class="text-gray-600 ml-4">NAD+-dependent deacetylases with diverse acylation specificity</dd>
                        
                        <dt class="font-semibold text-gray-800">Bromodomains</dt>
                        <dd class="text-gray-600 ml-4">Protein domains that recognize acetylated lysine residues</dd>
                        
                        <dt class="font-semibold text-gray-800">HDAC Inhibitors</dt>
                        <dd class="text-gray-600 ml-4">Small molecules that block HDAC enzymatic activity</dd>
                    </dl>
                </div>

                <!-- Quick Facts -->
                <div class="sidebar-section bg-white rounded-lg p-6">
                    <h3 class="text-lg font-bold text-gray-800 mb-4">
                        <i class="fas fa-chart-bar text-purple-600 mr-2"></i>Quick Facts
                    </h3>
                    <ul class="space-y-2 text-sm text-gray-700">
                        <li><strong>Total HDACs:</strong> 18 enzymes in human genome</li>
                        <li><strong>Class I HDACs:</strong> Nuclear localization, transcriptional repression</li>
                        <li><strong>Sirtuin substrates:</strong> >4,000 identified acetylated proteins</li>
                        <li><strong>FDA approvals:</strong> 4 HDAC inhibitors for cancer treatment</li>
                        <li><strong>Clinical trials:</strong> >100 ongoing studies with HDAC inhibitors</li>
                    </ul>
                </div>

                <!-- Research Timeline -->
                <div class="sidebar-section bg-white rounded-lg p-6">
                    <h3 class="text-lg font-bold text-gray-800 mb-4">
                        <i class="fas fa-timeline text-purple-600 mr-2"></i>Research Timeline
                    </h3>
                    <ul class="space-y-2 text-sm text-gray-700">
                        <li><strong>1964:</strong> Discovery of histone acetylation</li>
                        <li><strong>1996:</strong> First HDAC1 cloning and characterization</li>
                        <li><strong>2000:</strong> Sirtuin NAD+ dependence discovered</li>
                        <li><strong>2006:</strong> First HDAC inhibitor (vorinostat) FDA approval</li>
                        <li><strong>2020s:</strong> Selective HDAC inhibitor development</li>
                    </ul>
                </div>
            </aside>
        </div>
    </div>

    <!-- Footer -->
    <footer class="bg-gray-800 text-white py-12 mt-16">
        <div class="container mx-auto px-4">
            <div class="grid grid-cols-1 md:grid-cols-3 gap-8">
                <!-- References -->
                <div class="md:col-span-2">
                    <h3 class="text-xl font-bold mb-4">References (Selection)</h3>
                    <ol class="space-y-2 text-sm text-gray-300">
                        <li>1. Seto & Yoshida (2014). Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol.</li>
                        <li>2. Haberland et al. (2009). The many roles of histone deacetylases in development and physiology. Nat Rev Genet.</li>
                        <li>3. Falkenberg & Johnstone (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov.</li>
                        <li>4. Imai et al. (2000). Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature.</li>
                    </ol>
                </div>

                <!-- Attribution -->
                <div>
                    <h3 class="text-xl font-bold mb-4">Image Attribution</h3>
                    <p class="text-sm text-gray-300 mb-4">
                        Header image: Chromatin decondensation super-resolution microscopy, Nature Scientific Reports, 
                        doi:10.1038/srep04477. Used under fair use for educational purposes.
                    </p>
                    
                    <!-- Navigation -->
                    <div class="flex flex-col space-y-2 text-sm">
                        <a href="#" class="text-blue-400 hover:text-blue-300">← Previous Review: Histone PTMs Comprehensive Review</a>
                        <a href="#" class="text-blue-400 hover:text-blue-300">Next Review: Epigenetic Inheritance Complete →</a>
                        <a href="#" class="text-blue-400 hover:text-blue-300">Category: Epigenetics & Gene Regulation</a>
                    </div>
                </div>
            </div>
            
            <div class="border-t border-gray-700 mt-8 pt-8 text-center text-sm text-gray-400">
                <p>&copy; 2025 CellNucleus.com - Comprehensive Nuclear Biology Resource</p>
            </div>
        </div>
    </footer>

    <script>
        // Smooth scrolling for anchor links
        document.querySelectorAll('a[href^="#"]').forEach(anchor => {
            anchor.addEventListener('click', function (e) {
                e.preventDefault();
                const target = document.querySelector(this.getAttribute('href'));
                if (target) {
                    target.scrollIntoView({
                        behavior: 'smooth',
                        block: 'start'
                    });
                }
            });
        });

        // Reading progress indicator
        window.addEventListener('scroll', function() {
            const scrollTop = window.pageYOffset;
            const docHeight = document.body.offsetHeight;
            const winHeight = window.innerHeight;
            const scrollPercent = scrollTop / (docHeight - winHeight);
            const progressBar = document.createElement('div');
            
            if (!document.querySelector('.progress-bar')) {
                progressBar.className = 'progress-bar fixed top-0 left-0 h-1 bg-purple-600 z-50 transition-all duration-300';
                progressBar.style.width = (scrollPercent * 100) + '%';
                document.body.appendChild(progressBar);
            } else {
                document.querySelector('.progress-bar').style.width = (scrollPercent * 100) + '%';
            }
        });
    </script>
</body>
</html>
    <script id="html_badge_script1">
        window.__genspark_remove_badge_link = "https://www.genspark.ai/api/html_badge/" +
            "remove_badge?token=To%2FBnjzloZ3UfQdcSaYfDhxYpmyTccV1BDaFtMc9BsKjBVGJGmQB1VzPfXH6WI%2FSbJ7O0EQhsoW7e1Esq2FctGwbzdybJJa9W3cVghJu7PMtdhDDtjoUTDXNARLUFjS%2FAoNR8qqQ9R6wRMx8PJKUpz4ujYe5gyRErYTQepOl9Ct3yQ2hEoU9N5srZGbSSt3iVQbubzJvbHzIDPypXos3sT94CBPtAGhv1f3NnRfREuaqS1UY1FLOK5cmbiWZRHN7I5mLWKWpAiYYZ9C6aXUUGgmYg0nw43aF7E3D3DhRW6YE6D1%2BQQrV3WBzc8ngVyOIb%2BEmXnAMoqPSwEWRaehQ9C06YQXtHYwwoCL46zSLoTP06%2BQHTvsYd%2FT487wSiKy5sgBlm%2Fk0fW01ekX%2BLeG3IgdVFk4o%2BEg9%2FvXJZoEYptDGjXQFwZGaruf%2Bp5ZvdrDAlof1tVH8UJInD5Y%2FOZ9NCjmLrTersb48%2FYzweE%2BtxijX3pKk%2BV8rkPgUsoZ%2FdVadMyzdjEqdCsbCxkpHfmaa302Z2kHgCAA%2BcyoJOozZGBg%3D";
        window.__genspark_locale = "en-US";
        window.__genspark_token = "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";
    </script>
    
    <script id="html_notice_dialog_script" src="https://www.genspark.ai/notice_dialog.js"></script>
    